• Researcher Profile

    Amy L. Billett, MD

    Amy L. Billett, MD

    Top Doctor

    Director of Safety and Quality, Division of Pediatric Hematology/Oncology
    Institute Physician

    Associate Professor of Pediatrics, Harvard Medical School


    Pediatric Hematologic Malignancies

    Office phone: 617-632-5640
    Fax: 617-632-4811
    Email: amy_billett@dfci.harvard.edu

    Preferred contact method: office phone

    View Physician Profile

    Research Department

    Pediatric Oncology


    Lymphoma (Hodgkin and Non-Hodgkin), Quality improvement, Patient safety, Electronic health records, Management of nausea and vomiting, Global health

    Area of Research

    Hodgkin's Disease in Children, CLABSI-reduction

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Shields Warren 360
    Boston, MA 02215


    Dr. Billett received her MD from Harvard Medical School in 1984. After completing a residency in pediatrics at the University of Washington Hospitals, she completed a fellowship in pediatric hematology-oncology at Children's Hospital Boston and Dana-Farber Cancer Institute and became a staff physician in the pediatric hematology/oncology program in 1990. She was the medical director of the inpatient oncology service at Children's Hospital 1995-2005.

    Dr. Billett has participated in multiple projects involving improving systems of care, including development of a pediatric chemotherapy order entry system, implementation of the joint CH-DFCI pediatric electronic health record. She is currently the medical director for patient safety and quality in the pediatric hematology/oncology program, the leader of the pediatric lymphoma program, and an active clinician in the program.

    She is a clinical faculty leader of the newly established national collaborative to reduce catheter-associated blood stream infections in pediatric hematology/oncology patients.

    Recent Awards

    • Leadership Development for Physicians, Harvard Medical School, Boston, MA, 2003


    Hodgkin's Disease in Children, CLABSI-reduction

    Our program has been an active member of a small national consortium for clinical trials in pediatric Hodgkins since 1990. pediatric Hodgkin's disease. We currently have three open trials looking at improving/maintaining efficacy while minimizing long-term toxicity.

    Our center is a founding member of a national quality improvement collaborative started in 2009 to reduce catheter-associated blood stream infections in pediatric hematology-oncology patients. The focus of the collaborative is reliable implementation of best central line maintenance care.

View Physician Directory

Find a Clinical Trial

Support Cancer

Give Now